Related Experiment Video

Updated: Jun 5, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Antiplatelet therapy in coronary heart disease prevention

Kumaran Kolandaivelu1, Deepak L Bhatt

  • 1Division of Cardiology, Brigham and Women's Hospital, Boston, MA 02115, USA.

Cardiology Clinics
|January 25, 2011
PubMed

Insights

Antiplatelet therapies help manage coronary heart disease (CHD) and atherothrombosis. However, significant challenges remain in optimizing their use for effective prevention in clinical practice.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Platelets play a critical role in the development of coronary heart disease (CHD).
  • Atherothrombosis management relies heavily on antiplatelet therapies.
  • Despite advances, a substantial number of individuals experience recurrent coronary events annually.

Purpose of the Study:

  • To review current antiplatelet drug utilization in coronary heart disease (CHD) prevention.
  • To identify barriers hindering the optimal application of antiplatelet therapies in real-world settings.

Main Methods:

  • This study is a review of current literature and clinical practice regarding antiplatelet therapy.
  • It synthesizes information on drug efficacy, dosing, and combinations for CHD prevention.
  • The review also examines practical challenges in implementing these therapies.

Main Results:

  • Antiplatelet agents are integral to managing atherothrombosis in acute and preventive settings.
  • A significant burden of initial and recurrent coronary events persists despite existing treatments.
  • Barriers to optimal antiplatelet therapy use in clinical practice are identified.

Conclusions:

  • Optimizing antiplatelet therapy is crucial for improving outcomes in coronary heart disease (CHD) prevention.
  • Addressing identified barriers is essential to fully realize the potential of antiplatelet drugs.
  • Further strategies are needed to enhance the real-world effectiveness of these therapies.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...